Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.

Based in the US, the target company is focused on developing treatments for rare diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The purchase consideration for the acquisition is fixed at $825m, which includes an upfront payment of $400m and the remaining contingent on the achievement of certain milestones related to development, regulatory and sales.

True North’s drug candidate TNT009 aims to treat a rare blood disorder known as CAD and will strengthen Boverativ’s portfolio as a result of the acquisition.

"Irish biopharmaceutical company Horizon Pharma has reached an agreement to sell one of its European subsidiaries to Chiesi Farmaceutici, a pharmaceutical company based in Italy."

Also based in the US, Bioverativ is a biopharmaceutical company focused on developing therapies for haemophilia and other rare blood disorders.

See Also:

Irish biopharmaceutical company Horizon Pharma has reached an agreement to sell one of its European subsidiaries to Chiesi Farmaceutici, a pharmaceutical company based in Italy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The subsidiary owns the marketing rights to PROCYSBI delayed-release capsules and QUINSAIR, a levofloxacin inhalation solution, in Europe, the Middle East and Africa (EMEA).

Chiesi Farmaceutici believes the transaction will help further strengthen its rare disease offering in the EMEA regions.

The purchase consideration for the transaction includes $70m in upfront payment and additional potential payments based on the achievement of sales-based milestones.